Literature DB >> 17591649

Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial.

B M Glover1, S J Walsh, C J McCann, M J Moore, G Manoharan, G W N Dalzell, A McAllister, B McClements, D J McEneaney, T G Trouton, T P Mathew, A A J Adgey.   

Abstract

AIMS: To compare the efficacy and safety of an escalating energy protocol with a non-escalating energy protocol using an impedance compensated biphasic defibrillator for direct current cardioversion of atrial fibrillation (AF). METHODS AND
RESULTS: This prospective multicentre randomised trial enrolled 380 patients (248 male, mean (SD) age 67 (10) years) with AF. Patients were randomised to either an escalating energy protocol (protocol A: 100 J, 150 J, 200 J, 200 J), or a non-escalating energy protocol (protocol B: 200 J, 200 J, 200 J). Cardioversion was performed using an impedance compensated biphasic waveform. First-shock success was significantly higher for those randomised to 200 J than 100 J (71% vs 48%; p<0.01) and for patients with a body mass index (BMI) >25 kg/m(2) (75% vs 44%; p = 0.01). In patients with a normal BMI there was no significant difference in first-shock success. There was also no significant difference between subsequent shocks or overall success. The use of a non-escalating protocol (protocol B) resulted in fewer shocks but with a higher cumulative energy. There was no difference in duration of procedure, amount of sedation administered or post-shock erythema between the groups.
CONCLUSION: First-shock success was significantly higher, particularly in patients with a BMI >25 kg/m(2), when a non-escalating initial 200 J energy was selected. The overall success, duration of procedure and amount of sedation administered, however, did not differ significantly between the two protocols.

Entities:  

Mesh:

Year:  2007        PMID: 17591649     DOI: 10.1136/hrt.2007.120782

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

Review 1.  [Treatment of atrial fibrillation in intensive care units and emergency departments].

Authors:  M Arrigo; D Bettex; A Rudiger
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-04-16       Impact factor: 0.840

2.  Association between transthoracic impedance and electrical cardioversion success with biphasic defibrillators: An analysis of 1055 shocks for atrial fibrillation and flutter.

Authors:  Mouhannad M Sadek; Varsha Chaugai; Mark J Cleland; Timothy J Zakutney; David H Birnie; F Daniel Ramirez
Journal:  Clin Cardiol       Date:  2018-05-11       Impact factor: 2.882

Review 3.  Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation.

Authors:  Andrea Tampieri; Anna Maria Rusconi; Tiziano Lenzi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

4.  Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol.

Authors:  F Daniel Ramirez; Mouhannad M Sadek; Isabelle Boileau; Mark Cleland; Pablo B Nery; Girish M Nair; Calum J Redpath; Martin S Green; Darryl R Davis; Karen Charron; Joshua Henne; Timothy Zakutney; Rob S B Beanlands; Benjamin Hibbert; George A Wells; David H Birnie
Journal:  Europace       Date:  2019-05-01       Impact factor: 5.214

5.  Cardioversion of Atrial Fibrillation and Flutter: Comparative Study of Pulsed vs. Low Energy Biphasic Truncated Exponential Waveforms.

Authors:  Delphine Lavignasse; Elina Trendafilova; Elena Dimitrova; Vessela Krasteva
Journal:  J Atr Fibrillation       Date:  2019-10-31

6.  Cardioversion Efficacy Using Pulsed Biphasic or Biphasic Truncated Exponential Waveforms: A Randomized Clinical Trial.

Authors:  Anders S Schmidt; Kasper G Lauridsen; Kasper Adelborg; Peter Torp; Leif F Bach; Simon M Jepsen; Nete Hornung; Charles D Deakin; Hans Rickers; Bo Løfgren
Journal:  J Am Heart Assoc       Date:  2017-03-08       Impact factor: 5.501

Review 7.  Management of atrial fibrillation in critically ill patients.

Authors:  Mattia Arrigo; Dominique Bettex; Alain Rudiger
Journal:  Crit Care Res Pract       Date:  2014-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.